Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
3440 studies found for:    novartis
Show Display Options
Rank Status Study
21 Recruiting Safety and Immunogenicity of Novartis Meningococcal Group B Vaccine When Administered Concomitantly With Novartis MenACWY Conjugate Vaccine to Healthy Infants
Condition: Meningococcal Disease
Interventions: Biological: rMenB+OMV  and MenACWY;   Biological: rMenB+OMV;   Biological: MenACWY
22 Recruiting Safety and Immunogenicity of Novartis Meningococcal B Vaccine When Administered to Immunocompromised Children and Adolescents Compared to Healthy Subjects
Condition: Meningococcal Disease
Intervention: Biological: rMenB+OMV
23 Completed
Has Results
Novartis Vaccine and Diagnostics Carriage Trial
Condition: N. Meningitidis Carriage
Interventions: Biological: Meningococcal B Recombinant + Outer Membrane Vesicle vaccine (rMenB+OMV NZ);   Biological: MenACWY-CRM conjugate vaccine;   Biological: Japanese Encephalitis vaccine
24 Recruiting Safety and Immunogenicity of Two Doses of aH5N1 Vaccine in Adult and Elderly Subjects With and Without Immunosuppressive Conditions *aH5N1:Monovalent H5N1 Influenza Vaccine
Conditions: Influenza, Human;   Flu, Human;   Flu, Avian;   Influenza;   Influenza A Virus, H5N1 Subtype
Interventions: Biological: Novartis Investigational H5N1 vaccine;   Biological: Novartis Seasonal Influenza Vaccine
25 Completed
Has Results
Safety and Immune Response of Novartis MenACWY-CRM Conjugate Vaccine When Given to Healthy Toddlers
Condition: Meningococcal Infections
Interventions: Biological: MenACWY-CRM + MMRV;   Biological: MMRV;   Biological: MenACWY-CRM
26 Completed
Has Results
A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Vaccine In Infants
Condition: Meningitis, Meningococcal
Interventions: Biological: Meningococcal ACWY Conjugate Vaccine;   Biological: DTaP-IPV-HBV;   Biological: Hib;   Biological: Rotavirus;   Biological: Pneumococcal 7-valent Conjugate Vaccine;   Biological: HAV;   Biological: MMR-V;   Biological: DTaP
27 Completed Novartis Pandemic Influenza A (H1N1) Vaccine(s) Observational Comparative Safety Study
Condition: Influenza
Intervention: Other: Non-intervention observational study
28 Completed
Has Results
Safety, Tolerability and Immunogenicity of Three Doses of Novartis Meningococcal B Vaccine When Administered to Healthy At-risk Adults
Condition: Meningococcal Disease
Interventions: Biological: Men ACWY CRM;   Biological: 4CMenB
29 Completed Immunogenicity, Safety and Lot to Lot Consistency of Novartis Meningococcal B Recombinant Vaccine When Administered With Routine Infant Vaccinations to Healthy Infants
Condition: Meningococcal Disease
Interventions: Biological: Serogroup B meningococcal Vaccine lot 1 (rMenB Lot 1);   Biological: Serogroup B meningococcal Vaccine lot 2 (rMenB Lot 2);   Biological: Serogroup B meningococcal Vaccine lot 3 (rMenB Lot 3);   Biological: Routine vaccination;   Biological: Meningococcal group C
30 Completed Extension Study of V72P13 to Evaluate the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine When Administered as a Booster or as a Two-dose Catch-up to Healthy Toddlers
Condition: Meningococcal Disease
Interventions: Biological: 1a - rMenB+OMV NZ and routine infant vaccinations;   Biological: 1b - rMenB+OMV NZ and routine infant vaccinations;   Biological: 2a - Routine infant vaccinations and rMenB+OMV NZ;   Biological: 2b - rMenB+OMV NZ and routine infant vaccinations;   Biological: 3a - rMenB+OMV NZ and routine infant vaccinations;   Biological: 3b - 1 dose of rMenB+OMV NZ plus routine infant vaccinations;   Biological: 4a- rMenB+OMV NZ and routine infant vaccinations;   Biological: 4b - rMenB+OMV NZ and routine infant vaccinations
31 Completed
Has Results
Study to Evaluate the Safety of Novartis MenACWY Conjugate Vaccine When Administered With Routine Infant Vaccinations to Healthy Infants
Conditions: Meningitis;   Meningococcal Infection
Interventions: Biological: MenACWY-CRM197;   Biological: DTaP (Diptheria, Tetanus, Pertussis) Vaccine;   Biological: Hib (Haemophilus influenza b) Vaccine;   Biological: IPV (Inactivated Polio Vaccine) Vaccine;   Biological: Pneumococcal conjugate Vaccine;   Biological: MMR (Measles, Mumps, and Rubella) Vaccine;   Biological: Varicella Vaccine;   Biological: Hepatitis A Virus
32 Recruiting Safety of One Dose of Meningococcal ACWY Conjugate Vaccine in Subjects From 11 to 55 Years of Age in the Republic of South Korea
Condition: Meningococcal Disease
Intervention: Biological: Novartis Meningococcal ACWY Conjugate Vaccine (Menveo)
33 Active, not recruiting Safety and Immunogenicity of Two Doses of aH5N1 Vaccine in Adult and Elderly Subjects With and Without Underlying Medical Conditions
Conditions: Influenza,;   Flu,
Interventions: Biological: Novartis Investigational H5N1 vaccine;   Biological: Novartis Seasonal Influenza Vaccine
34 Completed Bioequivalence of Vildagliptin Tablet Manufactured in China Compared to Imported Vildagliptin Tablet in Chinese Healthy Volunteers
Condition: Healthy
Intervention: Drug: Vildagliptin (LAF237)
35 Completed
Has Results
Persistence Of Antibody Responses Among Children Who Previously Received Novartis MenACWY Conjugate Vaccine or Meningococcal C Conjugate Vaccine
Condition: Meningococcal Disease
Intervention: Biological: MenACWY-CRM
36 Completed
Has Results
A Phase 3b, Single-Center, Open-label Study to Assess the Immunogenicity and Safety of Novartis Meningococcal B Recombinant Vaccine When Administered at a 0, 2-Month Schedule in Healthy At-Risk Adults Aged 18 to 65 Years Inclusive.
Condition: Prevention of the Meningococcal Disease
Intervention: Biological: rMenB+OMV NZ
37 Recruiting Trial to Assess Immunogenicity and Safety of Novartis Meningococcal ABCWY Vaccine as Compared to Meningococcal B Vaccine in Adolescents
Condition: Meningococcal Disease
Interventions: Biological: rMenB+OMV;   Other: Placebo;   Biological: Hep A;   Biological: ABCWy
38 Completed
Has Results
A Multi-center, Observer-blind, Placebo-controlled, Randomized Study to Evaluate the Immunogenicity and Safety of MenACWY in Adolescents and Adults in Korea
Conditions: Meningococcal Disease;   Meningococcal Meningitis
Interventions: Biological: Novartis MenACWY-CRM;   Biological: Saline Placebo
39 Completed A 16 Week Evaluation of the Novartis Health Management Tool (HMT) in Age Related Macular Degeneration (AMD)
Condition: Age Related Macular Degeneration (AMD)
Intervention: Device: Health Management Tool (HMT)
40 Active, not recruiting A Phase 3b Study to Assess the Safety of Novartis Meningococcal B Recombinant Vaccine When Administered in Healthy At-risk Adults
Conditions: Meningococcal Disease;   Meningococcal Meningitis
Intervention: Biological: Recombinant meningococcal B + OMV NZ

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years